Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Monika Engelhardt"'
Autor:
Gabriele Ihorst, Justus Duyster, Robert Zeiser, Tim Struessmann, Reinhard Marks, Sophie Ewald, Jürgen Finke, Monika Engelhardt, Miguel Waterhouse, Jesus Duque-Afonso, Joachim Müller-Quernheim, Ralph Wäsch, Hartmut Bertz
Publikováno v:
Blood Advances. 5:4327-4337
High-dose chemotherapy, followed by autologous hematopoietic stem cell transplantation (auto-HSCT), is an established therapy for patients with hematological malignancies. The age of patients undergoing auto-HSCT and, therefore, the comorbidities, ha
Autor:
Martin Kaiser, Baldeep Wirk, Monika Engelhardt, Bruno Paiva, Laurent Garderet, S. Vincent Rajkumar, Maria-Victoria Mateos, Philippe Moreau, Carlos Fernández de Larrea, Robert A. Kyle, Jo Caers, Wilson I. Gonsalves, Hermann Einsele, Hartmut Goldschmidt, Giampaolo Merlini, Suzanne Lentzch, Ashraf Badros, Saad Z. Usmani, Joan Bladé, Pellegrino Musto, Fredrik Schjesvold, Pieter Sonneveld, Jesús F. San Miguel, Laura Rosiñol, Gösta Gahrton, Patrick Hayden, Enrique M. Ocio, Brian G.M. Durie, Sascha A. Tuchman
Publikováno v:
Blood Cancer J . 2021 Dec 2;11(12):192
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Blood Cancer Journal
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (12), ⟨10.1038/s41408-021-00587-0⟩
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, 11(12):192. Nature Publishing Group
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Blood Cancer Journal
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (12), ⟨10.1038/s41408-021-00587-0⟩
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, 11(12):192. Nature Publishing Group
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position pa
Autor:
Antje Blank, Hartmut Goldschmidt, Stefan Härtle, Igor Wolfgang Blau, Tiantom Jarutat, Hermann Einsele, Katja Weisel, Manik Chatterjee, Christoph Röllig, Marc S. Raab, Johannes Weirather, Janine Griese, Christian Peschel, Monika Engelhardt, Hermine Agis, Barbara Ferstl, Mark Winderlich, Natalie Schub
Publikováno v:
The Lancet Haematology. 7:e381-e394
Summary Background Treatment of multiple myeloma is not curative, but targeting CD38 improves patient survival. To further explore this therapeutic approach, we investigated the safety and activity of MOR202, a novel monoclonal antibody targeting CD3
Autor:
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrian Alegre Amor, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Besisik, Michele Cavo, Javier De La Rubia Comos, Meletios A. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Facon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hajek, Guner Hayri Ozsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Stefan Knop, Marie-Christine Kyrtsonis, Juan Jose Lahuerta, Xavier Leleu, Carmen Martinez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique Minnema, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlivan, Ludek Pour, Henk Th.J. Roerdink, Laura Rosinol Dacsh, Hans Salwender, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tulin Tuglular, Ali Unal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group
Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c27bb717191298826d5623e5b11470
http://hdl.handle.net/10261/261314
http://hdl.handle.net/10261/261314
Autor:
Christine Greil, Monika Engelhardt, Reinhard Marks, Ralph Wäsch, Hermann Einsele, Hartmut Bertz, Robert Zeiser, Gabriele Ihorst, Justus Duyster, Katja Schoeller, Jürgen Finke
Publikováno v:
Haematologica
Despite significantly improved survival and response rates in patients diagnosed with multiple myeloma, it still remains an incurable disease with a poor outcome, especially in high-risk groups. Allogeneic stem cell transplantation offers a potential
Autor:
Milena Pantic, Julius Wehrle, Sabine Bleul, Martin Werner, Justus Duyster, Valerie Hupfer, Konrad Aumann, Nikolas von Bubnoff, Dietmar Pfeifer, Cornelius F. Waller, Christoph Niemöller, Jürgen Finke, Gabriele Ihorst, Nora Rebeka Javorniczky, Monika Engelhardt, Heike L. Pahl, Heiko Becker
Publikováno v:
Leukemia research. 98
Of BCR-ABL negative myeloproliferative neoplasm (MPN) patients, 3-14 % display a concomitant monoclonal gammopathy (MGUS). Nonetheless, literature on co-occurring MPN and MGUS is scarce, the molecular underpinnings are unknown and it is unclear wheth
Autor:
Ralph Wäsch, Emanuel Bisse, Efstathios Kastritis, Felix Gaiser, Gabriele Ihorst, Heinz Ludwig, Monika Engelhardt, Christine Greil, Ulrich Salzer
Publikováno v:
European Journal of Haematology. 99:449-458
Objective The heavy/light chain (HLC)-immunoassay quantifies light chain types of each immunoglobulin class in patients with monoclonal gammopathies. Methods We assessed 147 consecutive patients with different forms and stages of plasma cell dyscrasi
Autor:
Reinhard Marks, Axel J. Baumgarten, Roland Mertelsmann, Monika Engelhardt, Gabriele Ihorst, Kristina Fritsch, Tim Strüßmann, Thomas Fietz, Justus Duyster, Jürgen Finke
Publikováno v:
British Journal of Haematology. 178:927-935
Summary The optimal therapeutic approach for young diffuse large B-cell lymphoma (DLBCL) patients with high-intermediate and high-risk age-adjusted international prognostic index (aaIPI) remains unknown. Hereby we report a 10-year single-centre study
Autor:
Hans Salwender, Heinz Dürk, Hermann Einsele, Monika Engelhardt, Wolf Rösler, Georg Maschmeyer, Georg Hess, Bernd Metzner, Jürgen Müller, Bernd Hertenstein, Christina Hart, Martin Gramatzki, Wolfram Jung, Lars Olof Mügge, Martin Kropff, Peter Liebisch, Stefan Knop, Christian Langer, Holger Hebart, Martin Bentz, Elke Jäger, Christoph Tapprich, Christian Straka, Michael Pfreundschuh, Thomas Fischer, Lothar Kanz, Hans-Heinrich Wolf
Publikováno v:
British journal of haematology. 179(4)
Summary We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21-day cycles of VCD prior to autologous s
Autor:
Reinhard Marks, Monika Engelhardt, Jürgen Finke, Ralph Wäsch, Gabriele Ihorst, Alexandros Spyridonidis, Carsten Grüllich, Hartmut Bertz
Publikováno v:
Biology of Blood and Marrow Transplantation. 18:894-902
Peripheral blood stem cells (PBSCs) are increasingly used as the graft source in allogeneic hematopoietic cell transplantation. We compared long-term outcome after unrelated donor transplantation of 85 consecutive patients with acute myelogenous leuk